Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.

It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…

European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the EMA post-Brexit.

Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff.

Argenx has filed to raise up to $75 million in a Nasdaq IPO to take lead candidate ARGX-113 to the cusp of a pivotal trial.

Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech…

A phase 2 trial of Bristol-Myers' NASH candidate BMS-986036 met its primary endpoint.

Gilead Sciences has unveiled the first proof-of-concept data for its novel drug candidate for nonalcoholic steatohepatitis (NASH) as it tries to rebuild…

EMA's drug approval committee has indicated it is likely to reject XBiotech’s metastatic colorectal cancer candidate.